Top-Rated StocksTop-RatedNASDAQ:NTRA Natera (NTRA) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free NTRA Stock Alerts $90.12 +0.60 (+0.67%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$88.70▼$91.0050-Day Range$60.89▼$91.6652-Week Range$36.90▼$93.48Volume840,309 shsAverage Volume1.49 million shsMarket Capitalization$10.88 billionP/E RatioN/ADividend YieldN/APrice Target$78.36 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Natera alerts: Email Address Natera MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside13.1% Downside$78.36 Price TargetShort InterestBearish7.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 17 Articles This WeekInsider TradingSelling Shares$26.21 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.43) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector814th out of 947 stocksDiagnostics & Research Industry1st out of 2 stocks 2.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.36, Natera has a forecasted downside of 13.1% from its current price of $90.12.Amount of Analyst CoverageNatera has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.08% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Natera has recently increased by 9.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 3.1 News and Social Media Coverage News SentimentNatera has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Natera this week, compared to 5 articles on an average week.Search Interest31 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 417% compared to the previous 30 days.MarketBeat Follows19 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 533% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,206,633.00 in company stock.Percentage Held by InsidersOnly 9.42% of the stock of Natera is held by insiders.Percentage Held by Institutions92.59% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($2.43) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -23.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -23.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 14.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Natera Stock (NASDAQ:NTRA)Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Read More NTRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRA Stock News HeadlinesMarch 17, 2024 | insidertrades.comNatera, Inc. (NASDAQ:NTRA) Chairman Matthew Rabinowitz Sells 1,012 SharesMarch 17, 2024 | insidertrades.comSteven Leonard Chapman Sells 83,223 Shares of Natera, Inc. (NASDAQ:NTRA) StockMarch 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.March 18, 2024 | msn.comGenetic Testing Stock Nears Buy Point After Earnings Gap Up And 45% GainMarch 18, 2024 | stockhouse.comNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera(TM) in Stage II Colorectal CancerMarch 18, 2024 | finance.yahoo.comNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerMarch 16, 2024 | finance.yahoo.comNTRA Apr 2024 90.000 putMarch 16, 2024 | finance.yahoo.comNTRA Apr 2024 87.500 callMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 16, 2024 | finance.yahoo.comNTRA Apr 2024 80.000 putMarch 15, 2024 | finance.yahoo.comNTRA Mar 2024 82.500 callMarch 14, 2024 | finance.yahoo.comNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseMarch 14, 2024 | americanbankingnews.comNatera (NASDAQ:NTRA) Stock Rating Lowered by StockNews.comMarch 12, 2024 | finance.yahoo.comNatera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersMarch 12, 2024 | businesswire.comNatera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersMarch 10, 2024 | finance.yahoo.comNTRA Oct 2024 97.500 callMarch 10, 2024 | americanbankingnews.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells $249,705.36 in StockMarch 9, 2024 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) CEO Sells $824,045.36 in StockMarch 8, 2024 | finance.yahoo.comSEC and Chief Legal Officer Daniel Rabinowitz Sells Shares of Natera Inc (NTRA)March 7, 2024 | businesswire.comNatera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS PlanMarch 2, 2024 | finance.yahoo.comNatera Full Year 2023 Earnings: Beats ExpectationsMarch 1, 2024 | markets.businessinsider.comNatera’s Strong Q4 Performance and Positive Outlook Merit Buy Rating and $90 Price TargetMarch 1, 2024 | finance.yahoo.comDecoding Natera Inc (NTRA): A Strategic SWOT InsightFebruary 29, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Jazz Pharmaceuticals (JAZZ) and Natera (NTRA)February 29, 2024 | markets.businessinsider.comNatera’s Strong Q4 Performance and Market Positioning Warrant a Buy Rating with Increased Price TargetFebruary 29, 2024 | finance.yahoo.comNatera to Participate in March Investor ConferencesFebruary 29, 2024 | finance.yahoo.comNatera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call TranscriptSee More Headlines Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today3/19/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,282Year FoundedN/APrice Target and Rating Average Stock Price Target$78.36 High Stock Price Target$110.00 Low Stock Price Target$48.00 Potential Upside/Downside-13.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,800,000.00 Net Margins-40.16% Pretax Margin-40.14% Return on Equity-62.19% Return on Assets-31.88% Debt Debt-to-Equity Ratio0.37 Current Ratio4.10 Quick Ratio3.96 Sales & Book Value Annual Sales$1.08 billion Price / Sales10.05 Cash FlowN/A Price / Cash FlowN/A Book Value$6.37 per share Price / Book14.15Miscellaneous Outstanding Shares120,760,000Free Float109,383,000Market Cap$10.88 billion OptionableOptionable Beta1.39 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Matthew Rabinowitz Ph.D. (Age 51)Co-Founder & Executive Chairman Comp: $441.58kMr. Steven Leonard Chapman (Age 45)CEO & Director Comp: $1.15MMr. Michael B. Brophy M.B.A. (Age 44)Chief Financial Officer Comp: $611.35kMr. Daniel Rabinowitz L.L.M. (Age 55)Secretary & Chief Legal Officer Comp: $566.03kMr. John FeskoPresident & Chief Business OfficerMr. Jonathan Sheena M.Eng. (Age 51)Co-Founder & Director Comp: $293.91kMs. Olesya A. Anisimova CPAChief Accounting OfficerMr. Rishi KackerChief Technology OfficerMr. Eric A. EvansChief Scientific OfficerMr. Jerry DiffleyChief Compliance & Privacy OfficerMore ExecutivesKey CompetitorsExact SciencesNASDAQ:EXASQuest DiagnosticsNYSE:DGXLaboratory Co. of AmericaNYSE:LHFortreaNASDAQ:FTRERadNetNASDAQ:RDNTView All CompetitorsInsiders & InstitutionsSteven Leonard ChapmanSold 83,223 sharesTotal: $7.40 M ($88.96/share)Vanguard Group Inc.Bought 588,147 shares on 3/11/2024Ownership: 9.086%Matthew RabinowitzSold 1,012 sharesTotal: $89,420.32 ($88.36/share)Jonathan SheenaSold 1,028 sharesTotal: $90,834.08 ($88.36/share)Steven Leonard ChapmanSold 9,326 sharesTotal: $824,045.36 ($88.36/share)View All Insider TransactionsView All Institutional Transactions NTRA Stock Analysis - Frequently Asked Questions Should I buy or sell Natera stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NTRA shares. View NTRA analyst ratings or view top-rated stocks. What is Natera's stock price target for 2024? 13 equities research analysts have issued 12-month price objectives for Natera's stock. Their NTRA share price targets range from $48.00 to $110.00. On average, they predict the company's share price to reach $78.36 in the next twelve months. This suggests that the stock has a possible downside of 13.1%. View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts. How have NTRA shares performed in 2024? Natera's stock was trading at $62.64 at the beginning of 2024. Since then, NTRA stock has increased by 43.9% and is now trading at $90.12. View the best growth stocks for 2024 here. When is Natera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our NTRA earnings forecast. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) released its earnings results on Wednesday, November, 8th. The medical research company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.01. The medical research company had revenue of $268.30 million for the quarter, compared to the consensus estimate of $259.27 million. Natera had a negative trailing twelve-month return on equity of 62.19% and a negative net margin of 40.16%. The firm's revenue was up 27.4% on a year-over-year basis. During the same quarter last year, the company earned ($1.25) EPS. What ETFs hold Natera's stock? ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH). What guidance has Natera issued on next quarter's earnings? Natera updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN). When did Natera IPO? (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. Who are Natera's major shareholders? Natera's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.13%), Vanguard Group Inc. (9.09%), RTW Investments LP (2.16%), Kynam Capital Management LP (2.00%), Principal Financial Group Inc. (1.42%) and Norges Bank (1.12%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NTRA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.